Abstract
This article considers the role of adjuvant therapy in primary breast cancer, utilizing data from randomized prospective clinical trials as illustrative examples. The ongoing efforts targeted toward addressing some of the unresolved issues are underscored.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
-
Review
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / pathology
-
Breast Neoplasms / surgery
-
Clinical Trials as Topic / methods*
-
Combined Modality Therapy
-
Cyclophosphamide / administration & dosage
-
Doxorubicin / administration & dosage
-
Drug Administration Schedule
-
Female
-
Fluorouracil / administration & dosage
-
Hospitalization
-
Humans
-
Lymph Nodes / pathology
-
Melphalan / administration & dosage
-
Methotrexate / administration & dosage
-
Middle Aged
-
Prednisone / administration & dosage
-
Prospective Studies
-
Random Allocation
-
Tamoxifen / administration & dosage
-
Time Factors
-
Vereinigte Staaten
-
Vincristine / administration & dosage
Substances
-
Tamoxifen
-
Vincristine
-
Doxorubicin
-
Cyclophosphamide
-
Melphalan
-
Fluorouracil
-
Prednisone
-
Methotrexate
Supplementary concepts
-
CMFVP protocol
-
PMF protocol